Press coverage about ProNAi Therapeutics (NASDAQ:SRRA) has been trending positive on Tuesday, according to Accern. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. ProNAi Therapeutics earned a media sentiment score of 0.26 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 47.1852819283304 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
A number of brokerages have weighed in on SRRA. ValuEngine raised ProNAi Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Zacks Investment Research lowered ProNAi Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, October 26th. Finally, Jefferies Group raised ProNAi Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, October 23rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $4.00.
Shares of ProNAi Therapeutics (SRRA) traded down $0.03 during trading hours on Tuesday, hitting $2.97. The stock had a trading volume of 514,860 shares, compared to its average volume of 362,232. ProNAi Therapeutics has a fifty-two week low of $1.10 and a fifty-two week high of $3.41.
ProNAi Therapeutics (NASDAQ:SRRA) last announced its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.19) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.03. research analysts expect that ProNAi Therapeutics will post -0.85 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “ProNAi Therapeutics (NASDAQ:SRRA) Getting Favorable Media Coverage, Report Shows” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at https://www.dispatchtribunal.com/2017/12/05/favorable-news-coverage-somewhat-unlikely-to-affect-pronai-therapeutics-srra-stock-price.html.
About ProNAi Therapeutics
Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.
Receive News & Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.